氯二氟乙酸叔丁酯 | 167308-43-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 氯二氟乙酸叔丁酯
• 英文名称: t-butyl chlorodifluoroacetate
• 英文别名: tert-Butyl chlorodifluoroacetate；tert-butyl 2-chloro-2,2-difluoroacetate
• CAS: 167308-43-2
• 化学式: C₆H₉ClF₂O₂
• 分子量: 186.586
• InChiKey: CZLHJJSAELHRSE-UHFFFAOYSA-N

物化性质

• 沸点：
  65-70°C 10mm
• 密度：
  1.216±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• 海关编码：
  2915900090

反应信息

• 作为反应物：
  描述：

  ethyl 2-(4-(2-(5-hydroxythiophen-2-yl)-5-ethyl-6-methylpyrimidin-4-ylamino)phenyl)acetate 、 氯二氟乙酸叔丁酯 在 lithium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 ethyl 2-(4-(2-(5-(difluoromethoxy)thiophen-2-yl)-5-ethyl-6-methylpyrimidin-4-ylamino)phenyl)acetate
  参考文献：
  名称：

  Pyrimidine derivatives

  摘要：

  本发明的目的是提供一种对PDE4活性具有抑制作用且副作用较少的新型化合物。 该发明提供了一种由以下一般式（1）表示的化合物，其可能的立体异构体或外消旋体，其药理学上可接受的盐，水合物，溶剂化合物，或前药。

  公开号：

  US20060293343A1

文献信息

• INDAZOLE DERIVATIVES
  申请人：NAKANO Seiji

  公开号：US20100152265A1

  公开（公告）日：2010-06-17

  Compounds represented by the Formula (A-1) and the Formula (1) or salt thereof are provided. The compounds represented by the Formula (A-1) and the Formula (1) or salt thereof have a β3 adrenergic receptor agonist activity, and therefore are useful as an agent for the prevention and treatment of diabetes, obesity, hyperlipidemia, depression, biliary stone, a disorder derived from hyperactivity of biliary tract, a disorder derived from hyperactivity of digestive tract, interstitial cystitis, overactive bladder, urinary incontinence or a disorder derived from decreased tear secretion, etc.

  提供由化学式（A-1）和化学式（1）或其盐表示的化合物。由化学式（A-1）和化学式（1）或其盐表示的化合物具有β3肾上腺素能受体激动剂活性，因此可用作预防和治疗糖尿病、肥胖症、高脂血症、抑郁症、胆结石、胆道过度活动引起的疾病、消化道过度活动引起的疾病、间质性膀胱炎、膀胱过度活动、尿失禁或泪液分泌减少引起的疾病等。
• METHOD FOR PRODUCING DIFLUOROMETHYLENE COMPOUND
  申请人：SATO PHARMACEUTICAL CO., LTD.

  公开号：US20200190038A1

  公开（公告）日：2020-06-18

  The present invention provides a method for producing a difluoromethylene compound and an intermediate thereof, which are useful in the field of pharmaceuticals. Specifically provided is a method for producing a difluoromethylene compound, including a step of allowing a compound represented by formula (6): [wherein L 1 represents a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a cycloalkyl group, a lower alkoxy group, a halo-lower alkoxy group, or a hydroxy lower alkyl group; R 1 represents a lower alkyl group, a halogen atom, a halo-lower alkyl group, a cycloalkyl group, a cyano group, or a hydroxy lower alkyl group; and W represents a nitrogen atom or a methine group] to react with a compound represented by formula (7): [wherein R 2 represents a lower alkyl group, a halo-lower alkyl group, a cycloalkyl group, a lower alkenyl group, or an aralkyl group; and R 3 represents a chlorine atom, a bromine atom, or an iodine atom].

  本发明提供了一种用于生产二氟甲烯基化合物及其中间体的方法，该方法在药物领域中非常有用。具体提供了一种生产二氟甲烯基化合物的方法，包括以下步骤：允许由式（6）表示的化合物与由式（7）表示的化合物发生反应。在式（6）中，L1代表卤素原子、氰基、低碳基团、卤代低碳基团、环烷基团、低烷氧基团、卤代低烷氧基团或羟基低碳基团；R1代表低碳基团、卤素原子、卤代低碳基团、环烷基团、氰基或羟基低碳基团；W代表氮原子或甲基基团。在式（7）中，R2代表低碳基团、卤代低碳基团、环烷基团、低烯基基团或芳基基团；R3代表氯原子、溴原子或碘原子。
• INDAZOLE ANALOG
  申请人：Wada Yasuhiro

  公开号：US20120225909A1

  公开（公告）日：2012-09-06

  [Objective] To provide a drug that selectively stimulates the β3-adrenergic receptors, particularly a drug capable of preferentially stimulating the β3-adrenergic receptors over the α1-adrenergic receptors. This drug can be used in the treatment and prevention of diabetes, obesity, hyperlipidemia, depression, cholelithiasis, diseases caused by biliary hyperkinesia, diseases caused by hyperfunction of the gastrointestinal tract, interstitial cystitis, overactive bladder or urinary incontinence, diseases associated with decreased lacrimation, and the like. [Solution] Indazole analogs represented by the general formula (I) or a salt thereof. Drugs that contains these indazole analogs or a salt thereof as the active ingredient.

  【目的】提供一种选择性刺激β3-肾上腺素能受体的药物，特别是一种能够优先刺激β3-肾上腺素能受体而非α1-肾上腺素能受体的药物。该药可以用于糖尿病、肥胖症、高脂血症、抑郁症、胆石症、胆道高动力症引起的疾病、胃肠道高功能引起的疾病、间质性膀胱炎、过度活动的膀胱或尿失禁、伴有泪液减少的疾病等的治疗和预防。 【解决方案】一般式（I）所代表的吲唑类似物或其盐。包含这些吲唑类似物或其盐作为活性成分的药物。
• Process for preparing 2,2-difluoroketene silyl acetals and a,a-difluoro-b-silyloxy-1,3-dioxolane-4-propanoic acid esters
  申请人：ELI LILLY AND COMPANY

  公开号：EP0655454A1

  公开（公告）日：1995-05-31

  A process for preparing 2,2-difluoroketene silyl acetals and α,α-difluoro-β-silyloxy-1,3-dioxolane-4-propanoic acid esters using these acetals.

  一种利用 2,2-二氟酮硅基乙缩醛和 α,α-二氟-β-硅氧基-1,3-二氧戊环-4-丙酸酯制备工艺。
• INDAZOLE DERIVATIVE
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP2351742A1

  公开（公告）日：2011-08-03

  Compounds represented by the Formula (A-1) and the Formula (1) or salt thereof are provided. The compounds represented by the Formula (A-1) and the Formula (1) or salt thereof have a β3 adrenergic receptor agonist activity, and therefore are useful as an agent for the prevention and treatment of diabetes, obesity, hyperlipidemia, depression, biliary stone, a disorder derived from hyperactivity of biliary tract, a disorder derived from hyperactivity of digestive tract, interstitial cystitis, overactive bladder, urinary incontinence or a disorder derived from decreased tear secretion, etc.

  提供了由式（A-1）和式（1）或其盐代表的化合物。由式（A-1）和式（1）或其盐代表的化合物具有β3肾上腺素能受体激动剂活性，因此可用作预防和治疗糖尿病、肥胖症、高脂血症、抑郁症、胆道结石、胆道活动亢进引起的疾病、消化道活动亢进引起的疾病、间质性膀胱炎、膀胱过度活动症、尿失禁或泪液分泌减少引起的疾病等的药物。